Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification of H3N2 specific antibodies cross-reacting with H7 strains

ABSTRACT: Identification of H3N2 specific antibodies cross-reacting with H7 strains

PROVIDER: PRJNA267189 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Identification of H3N2 specific antibodies cross-reacting with H7 strains

Project description:Binding profile of H3N2 hemagglutinin (HA) reactive antibodies for various H3N2 and H7 HA proteins

2014-11-14 | GSE63249 | GEO

Influenza H3N2 infection of the Collaborative Cross founder strains reveals highly divergent host responses and identifies a unique phenotype in CAST/EiJ mice (blood)

Project description:To determine if genetic background can modulate severity of an infection, we studied the host responses to influenza infections in the eight genetically highly diverse Collaborative Cross (CC) founder mice. The CC founder (C57BL/6J, 129S1/SvlmJ, CAST/EiJ, PWK/PhJ) were intranasally infected with influenza A/HK/01/68 (H3N2) with 20Î¼l virus solution (1x101 ffu) or mock infected (with PBS). After infection lung was collected at different time points (mock_d3), d3, d5).

2015-12-31 | E-GEOD-74073 | biostudies-arrayexpress

Influenza H3N2 infection of the Collaborative Cross founder strains reveals highly divergent host responses and identifies a unique phenotype in CAST/EiJ mice (lung)

2015-12-31 | E-GEOD-74074 | biostudies-arrayexpress

Transcriptomes of genetically distinct E. coli O157:H7 strains

Project description:Transcriptomes of 24 clinical strains of E. coli O157:H7 that differ phylogenetically and by Shiga toxin profiles were compared after 30 min co-incubation with epithelial cells.

2010-07-22 | GSE20397 | GEO

Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity

Project description:Transcriptional profiling of peripheral blood mononuclear cells (PBMCs) from 30 subjects collected at day 0, day 1 and day 3 post yellow fever (YF) vaccination. Each patient sample is performed in duplicate to reduce the chance of error. Briefly, the project investigates how cross-reactive JE antibodies that are generated from prior vaccination can influence YF live-attenuated vaccine (LAV). The groups are hence segregated based on the YF antibody titers after 1 month vaccination. Group 4 refers to the control group where individuals received only the YF LAV. Enhancing group refers to the treatment group (given JE followed by YF vaccine), where individuals had YF antibody titers higher than 99% confidence interval of the YF antibody titers of the control group. Non-enhancing group, on the other hand, refers to the treatment group where individuals had YF antibody titers within or lower 99% confidence interval of the control group. Our present study provides evidence that enhancing levels of cross-reactive antibodies from prior Japanese encephalitis (JE) vaccination can improve subsequent YF immunogenicity. These microarray results indicate the genes and gene signatures that are associated with the differences in YF immunogenicity.

2017-09-05 | E-MTAB-4669 | biostudies-arrayexpress

Brevibacillus sp. H7 strain:H7

Project description:Brevibacillus sp. H7 strain:H7 Genome sequencing

| PRJNA1162698 | ENA

Hydrogenophaga sp. H7 strain:H7

Project description:Hydrogenophaga sp. H7 strain:H7 Genome sequencing and assembly

| PRJNA331085 | ENA

Hebeloma cylindrosporum h7 strain:h7

Project description:Hebeloma cylindrosporum h7 strain:h7 Genome sequencing and assembly

| PRJNA207849 | ENA

Hebeloma cylindrosporum h7 strain:h7

Project description:Hebeloma cylindrosporum h7 transcriptome